secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001558370-24-011350
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor Q2 2024: $11M loss, positive FDA pre-BLA meeting, DMD trial fully enrolled
--------------------------------------------------------------------------------

- Net loss $11.0M ($0.35/sh) in Q2 2024 vs $7.4M ($0.29) in Q2 2023; revenue $4.0M.
- Cash $29.5M at June 30, 2024 (down from $39.5M at Dec 31); raised $2.1M via ATM at $6.46/sh.
- Positive pre-BLA meeting with FDA for deramiocel; HOPE-3 Phase 3 fully enrolled (105 subjects).
- Top-line data from HOPE-3 Cohort A expected Q4 2024; 3-year HOPE-2 OLE showed +3.7 point PUL benefit.
- Cash runway into Q1 2025; added to Russell 2000/3000 indexes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837024011350/0001558370-24-011350-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837024011350/capr-20240807x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-011350

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer